Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer

被引:3
作者
Katsnelson, Marina [1 ]
Hwang, Wei-Ting [2 ]
Tahirovic, Emin [2 ]
Rubin, Stephen C. [3 ]
Tanyi, Janos L. [4 ]
机构
[1] Hosp Univ Penn, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA
[3] Fox Chase Canc Ctr, Dept Surg, Gynecol Canc, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Hosp Univ Penn, Dept Obstet & Gynecol, Div Gynecol Oncol, Philadelphia, PA 19104 USA
关键词
Predictors; survival ovarian cancer; secondary debulking; GYNECOLOGIC-ONCOLOGY-GROUP; SURGERY; CARCINOMA; THERAPY; CISPLATIN; TRIAL; CHEMOTHERAPY; MANAGEMENT; IMPROVES;
D O I
10.1080/01443615.2017.1336613
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This study aimed to examine the factors affecting feasibility of optimal and complete secondary cytoreductive surgery (SCRS) and to characterise the prognostic factors that correlate with improved survival in patients who underwent SCRS. This is a retrospective single-institutional cohort study of patients who underwent SCRS for recurrent epithelial ovarian cancer (EOC). One hundred and forty-eight patients met inclusion criteria. Platinum sensitivity was associated with complete cytoreduction at SCRS. Factors associated with suboptimal cytoreduction (SOC) were age >55 years, serous histology, largest tumour implant size >4cm, and SOC at primary surgery. Overall survival analysis showed significantly longer survival with complete cytoreduction compared to optimal and SOC. Surgical outcome of SCRS was an independent predictor of survival regardless of the outcome of primary cytoreduction. Location of the largest implant, DFI and timing of chemotherapy also impact on survival.
引用
收藏
页码:395 / 401
页数:7
相关论文
共 31 条
[11]   Trends in surgery and chemotherapy for women diagnosed with ovarian cancer in the united states [J].
Harlan, LC ;
Clegg, LX ;
Trimble, EL .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (18) :3488-3494
[12]   Surgery in recurrent ovarian cancer:: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial [J].
Harter, Philipp ;
du Bois, Andreas ;
Hahmann, Maik ;
Hasenburg, Annette ;
Burges, Alexander ;
Loibl, Sibylle ;
Gropp, Martina ;
Huober, Jens ;
Fink, Daniel ;
Schroeder, Willibald ;
Muenstedt, Karsten ;
Schmalfeldt, Barbara ;
Emons, Guenter ;
Pfisterer, Jacobus ;
Wollschlaeger, Kerstin ;
Meerpohl, Hans-Gerd ;
Breitbach, Georg-Peter ;
Tanner, Berno ;
Sehouli, Jalid ;
AGO, O. C. .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (12) :1702-1710
[13]   Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO [J].
Harter, Philipp ;
Sehouli, Jalid ;
Reuss, Alexander ;
Hasenburg, Annette ;
Scambia, Giovanni ;
Cibula, David ;
Mahner, Sven ;
Vergote, Ignace ;
Reinthaller, Alexander ;
Burges, Alexander ;
Hanker, Lars ;
Poelcher, Martin ;
Kurzeder, Christian ;
Canzler, Ulrich ;
Petry, Karl Ulrich ;
Obermair, Andreas ;
Petru, Edgar ;
Schmalfeldt, Barbara ;
Lorusso, Domenica ;
du Bois, Andreas .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (02) :289-295
[14]  
JANICKE F, 1992, CANCER-AM CANCER SOC, V70, P2129, DOI 10.1002/1097-0142(19921015)70:8<2129::AID-CNCR2820700820>3.0.CO
[15]  
2-U
[16]   The Role of Secondary Surgery in Recurrent Ovarian Cancer [J].
Lorusso, D. ;
Mancini, M. ;
Di Rocco, R. ;
Fontanelli, R. ;
Raspagliesi, F. .
INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2012, 2012
[17]   The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Mullerian Origin Treated With Neoadjuvant Chemotherapy [J].
Mahdi, Haider ;
Maurer, Kathryn A. ;
Nutter, Benjamin ;
Rose, Peter G. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (05) :823-829
[18]   2ND-LINE PLATINUM THERAPY IN PATIENTS WITH OVARIAN-CANCER PREVIOUSLY TREATED WITH CISPLATIN [J].
MARKMAN, M ;
ROTHMAN, R ;
HAKES, T ;
REICHMAN, B ;
HOSKINS, W ;
RUBIN, S ;
JONES, W ;
ALMADRONES, L ;
LEWIS, JL .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (03) :389-393
[19]  
Medina-Franco H, 2008, REV INVEST CLIN, V60, P212
[20]   SECONDARY CYTOREDUCTIVE SURGERY IN EPITHELIAL OVARIAN-CANCER - NONRESPONDERS TO 1ST-LINE THERAPY [J].
MORRIS, M ;
GERSHENSON, DM ;
WHARTON, JT .
GYNECOLOGIC ONCOLOGY, 1989, 33 (01) :1-5